Metabolic Syndrome Increases Short-Term Risks for CEA But Not CAS in Chinese Patients

0
0
0

Metabolic Syndrome Increases Short-Term Risks for Carotid Endarterectomy (CEA) But Not Stenting (CAS) in Chinese Patients

Stroke is a leading cause of death and disability worldwide, with 15–20% of ischemic strokes tied to carotid artery stenosis—narrowing of the main neck artery that supplies blood to the brain. For people with severe stenosis (50–99% for symptomatic cases, 70–99% for asymptomatic), two treatments are standard: carotid endarterectomy (CEA) (surgery to remove plaque) and carotid artery stenting (CAS) (a less invasive procedure using a mesh tube to keep the artery open). But how does metabolic syndrome (MetS)—a cluster of heart disease risk factors—affect the safety of these procedures? A 2020 study of over 2,000 Chinese patients offers new insights.

What Is Metabolic Syndrome?

Metabolic syndrome is diagnosed when someone has three or more of these conditions:

  • High blood pressure (systolic ≥140 mmHg or diastolic ≥90 mmHg)
  • High fasting blood sugar (≥110 mg/dL)
  • High triglycerides (≥150 mg/dL)
  • Low “good” cholesterol (HDL: <40 mg/dL for men, <50 mg/dL for women)
  • Obesity (BMI ≥30 kg/m²)

It’s a growing global health issue—linked to poor diet, inactivity, and aging—and doubles the risk of heart disease and stroke.

The Study: Who, What, and How

Led by researchers from the China International Neuroscience Institute and Xuanwu Hospital (Capital Medical University), the study analyzed data from 2,068 patients who underwent CEA (766 cases) or CAS (1,302 cases) between 2013 and 2017. All patients had severe carotid stenosis, confirmed by imaging (ultrasound, MRI, CT angiography, or digital subtraction angiography [DSA]).

The team focused on 30-day major adverse clinical events (MACEs)—a combined measure of death, stroke, or heart attack. They also tracked how MetS and its components (like diabetes or high blood pressure) influenced outcomes.

Key Findings

  1. Metabolic Syndrome Is Common—and Rising
    17.9% of patients (370 out of 2,068) had MetS. Importantly, the prevalence of MetS increased over time—a trend likely tied to changing lifestyles (e.g., more processed food, less physical activity) in China.

  2. CEA and CAS Have Similar Overall Safety

    • 3.4% of CEA patients (26/766) had a MACE within 30 days.
    • 3.1% of CAS patients (40/1,302) had a MACE.
      No statistically significant difference between the two treatments.

  3. MetS Raises Risks for CEA—but Not CAS
    For CEA patients, having MetS doubled the risk of MACEs (odds ratio [OR] = 2.476). Diabetes was another key risk factor (OR = 2.345)—over half (53.8%) of CEA patients with MACEs had diabetes, vs. 30.9% without MACEs.

    For CAS patients, MetS did not affect outcomes. Instead, three factors raised MACE risk:

    • High systolic blood pressure (143 mmHg vs. 135 mmHg in non-MACE patients).
    • History of coronary artery disease (CAD) (40% of MACE patients had CAD, vs. 21.6% without).
    • Twisted internal carotid artery (ICA tortuosity) (67.5% of MACE patients had a twisted artery, vs. 37.6% without).

What Do These Results Mean?

For patients and doctors, the findings highlight personalized treatment planning:

  • MetS patients considering CEA: MetS (and diabetes) increases short-term risks. Managing MetS components (e.g., lowering blood sugar, improving cholesterol) before surgery may help reduce complications.
  • MetS patients considering CAS: MetS itself isn’t a red flag—but controlling blood pressure and checking for CAD or artery twists is critical.

Why does MetS impact CEA but not CAS? Researchers suspect MetS causes systemic vascular dysregulation (e.g., stiffer arteries, poor blood flow) that makes surgery (which uses general anesthesia) riskier. CAS, a less invasive procedure done under local anesthesia, may avoid some of these systemic effects.

Limitations to Consider

Like all studies, this one has constraints:

  • Retrospective design: The team looked back at medical records, so they couldn’t control for all variables (e.g., how well patients managed MetS before surgery).
  • Short-term follow-up: Only 30-day outcomes were studied—long-term effects of MetS on CEA/CAS (e.g., restenosis or repeat strokes) are unknown.
  • MetS criteria: Current MetS definitions don’t include LDL (“bad”) cholesterol, which is key for carotid plaque. Future studies may need better ways to measure MetS in this context.

Final Takeaways

This is the largest study to link MetS to carotid revascularization outcomes in Chinese patients. The key message:

  • MetS is becoming more common in people needing CEA or CAS.
  • MetS is a risk factor for short-term complications after CEA—but not CAS.
  • For patients with MetS and severe carotid stenosis, talking to a doctor about treatment options (and managing MetS components) is essential.

Original study: Bai XS, Feng Y, Wang T, et al. Impact of metabolic syndrome on short-term outcome of carotid revascularization: a large sample size study in Chinese population. Chinese Medical Journal 2020;133(22):2688–2695. doi:10.1097/CM9.0000000000001038

Was this helpful?

0 / 0